Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

NASDAQ:APVO

Aptevo Therapeutics Inc

Last Close

1.13

03/05 20:00

Market Cap

3.55M

Beta: 5.32

Volume Today

1.93M

Avg: 60.96K

PE Ratio

0.07

PFCF: −0.27